Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
RNAi-based drug developer Arrowhead Research will pay Novartis $10 million in cash and $25 million in stock to acquire its RNAi portfolio. The deal includes intellectual property related to RNAi therapeutics and three preclinical drug candidates. Novartis built its RNAi portfolio, which includes the intellectual property related to 30 drug targets, through a five-year pact with another RNAi drug developer, Alnylam. During the course of that collaboration, which ended in 2010, Novartis paid Alnylam $125 million in R&D funding.
This article has been sent to the following recipient: